Mattox D E, Clark G M, Balcerzak S P, O'Bryan R M, Oishi N, Stuckey W J
Invest New Drugs. 1984;2(4):405-7. doi: 10.1007/BF00171594.
Twenty-two patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced squamous cell carcinoma of the head and neck. One patient had a partial response, one an improvement and twenty had progressive disease. The major toxicities were leukopenia and thrombocytopenia. There was no significant antitumor activity of Mitoxantrone in this group of patients with head and neck cancer, most of whom were previously treated with radiation and chemotherapy.
在一项米托蒽醌治疗晚期头颈部鳞状细胞癌的II期试验中，22例患者可评估疗效。1例患者部分缓解，1例病情改善，20例病情进展。主要毒性为白细胞减少和血小板减少。在这组头颈部癌患者中，米托蒽醌没有显著的抗肿瘤活性，其中大多数患者此前接受过放疗和化疗。
